What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
His primary areas of study are Cancer research, Internal medicine, Oncology, Cancer and Mutation.
The study incorporates disciplines such as Bioinformatics, Anaplastic lymphoma kinase, Carcinoma, Crizotinib and Lung cancer in addition to Cancer research.
His Bioinformatics study combines topics in areas such as Tyrosine kinase, KRAS, Breast cancer and Exon.
In general Oncology study, his work on ROS1 often relates to the realm of Gene expression profiling, thereby connecting several areas of interest.
His Cancer study incorporates themes from Fusion gene and Pathology.
Siraj M. Ali combines subjects such as Allele frequency, Epidermal growth factor receptor, Protein kinase domain and PDGFRA with his study of Mutation.
His most cited work include:
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (1097 citations)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (429 citations)
- Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors (387 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Cancer research, Internal medicine, Oncology, Cancer and Genomic profiling.
His Cancer research research integrates issues from Mutation, Gene, Exon and Lung cancer, Pathology.
Siraj M. Ali focuses mostly in the field of Lung cancer, narrowing it down to matters related to Adenocarcinoma and, in some cases, Lung.
As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Bioinformatics, and often DNA sequencing.
His biological study deals with issues like Carcinoma, which deal with fields such as Pembrolizumab.
His study in Breast cancer and CDKN2A is carried out as part of his Cancer studies.
He most often published in these fields:
- Cancer research (47.12%)
- Internal medicine (34.71%)
- Oncology (33.23%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (47.12%)
- Internal medicine (34.71%)
- Oncology (33.23%)
In recent papers he was focusing on the following fields of study:
Siraj M. Ali mainly focuses on Cancer research, Internal medicine, Oncology, Genomic profiling and Microsatellite instability.
The concepts of his Cancer research study are interwoven with issues in Cancer, Targeted therapy, CDKN2A, Gene and Exon.
His studies link PTEN with Cancer.
His Oncology research is multidisciplinary, relying on both Bladder cancer, KRAS, Chemotherapy and Immunotherapy.
His research integrates issues of Malignancy and Pathology in his study of Genomic profiling.
His Microsatellite instability research incorporates themes from Mutation, Sarcoma and PDGFRA.
Between 2018 and 2021, his most popular works were:
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. (122 citations)
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies (81 citations)
- Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers (57 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary areas of investigation include Cancer research, Internal medicine, Oncology, Microsatellite instability and Immunotherapy.
His Cancer research research incorporates elements of Cancer, Targeted therapy, KRAS, Gene and PTEN.
His research in Cancer intersects with topics in Gene duplication and Stromal cell.
His studies in Oncology integrate themes in fields like Mucinous Adenocarcinomas, Treatment outcome, Prostate tumors and Phases of clinical research.
Siraj M. Ali has included themes like Mutation, DNA Mutational Analysis and Colorectal cancer in his Microsatellite instability study.
His Immunotherapy study deals with Immunohistochemistry intersecting with EZH2, Bladder Squamous Cell Carcinoma, Deep sequencing and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
